These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10207271)

  • 1. Anemia and cardiovascular complications: iron and EPO impact.
    Kurtzman NA; Sabatini S
    Miner Electrolyte Metab; 1999; 25(1-2):109-13. PubMed ID: 10207271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutritional implications of recombinant human erythropoietin therapy in renal disease.
    Sanders HN; Rabb HA; Bittle P; Ramirez G
    J Am Diet Assoc; 1994 Sep; 94(9):1023-9. PubMed ID: 8071484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 6. Anemia and erythropoietin treatment in chronic kidney diseases.
    Santoro A; Canova C
    Minerva Urol Nefrol; 2005 Mar; 57(1):23-31. PubMed ID: 15944519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron therapy and cardiovascular disease.
    Sullivan JL
    Kidney Int Suppl; 1999 Mar; 69():S135-7. PubMed ID: 10084298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 10. [New treatments of anemia in chronic renal failure].
    Fernández Lorente L; Romero R
    Med Clin (Barc); 2014 Jul; 143(1):39-42. PubMed ID: 24467877
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythropoietin and anemia.
    Tong EM; Nissenson AR
    Semin Nephrol; 2001 Mar; 21(2):190-203. PubMed ID: 11245780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of renal anemia with erythropoietin].
    Spustova V; Kovac A
    Bratisl Lek Listy; 1999 Aug; 100(8):432-8. PubMed ID: 10645031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anemia and renal failure: efficacy of its control].
    Fort J
    Nefrologia; 2006; 26 Suppl 3():28-32. PubMed ID: 17469424
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoietin in kidney disease and type 2 diabetes.
    Schnuelle P; Benck U; Krämer BK
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin.
    Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J
    Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia in renal insufficiency.
    Santoro A
    Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.